Avanir Pharmaceuticals
 Home  About  Investors  Product R&D  Employment  Contact

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.

Avanir Producs

Approved Products

product indicator abreva® (docosanol 10% cream)

Investigational Products

product indicator Zenvia™ for PBA
product indicator MIF Inhibitor
product indicator Zenvia™ for Diabetic Peripheral Neuropathic Pain

product indicator Zenvia™ for Pseudobulbar Affect (PBA)

Learn more about the Star Trial clinical study that is now underway.

Webcasts

Lazard Capital Markets 6th Annual Healthcare Conference
Date: Nov 18, 2009
Begins: 3:15 p.m. ET

BIOCOM Investor Conference
Date: Oct 26, 2009
Begins: 2:30 p.m. ET

Latest News

Nov 17, 2009
AVANIR Pharmaceuticals Invites Investors to Fourth Quarter and Fiscal Year End Conference Call

Nov 11, 2009
AVANIR to Present at the Lazard Healthcare Conference

Nov 10, 2009
Avanir Pharmaceuticals Announces Zenvia Safety and Efficacy Data from Star Trial Open Label Extension

Home | About | Investors | Products | Employment | Contact
© 2002 Avanir Disclosure